<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02870400</url>
  </required_header>
  <id_info>
    <org_study_id>R2477-HV-1525</org_study_id>
    <nct_id>NCT02870400</nct_id>
  </id_info>
  <brief_title>A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Intravenously and Subcutaneously Administered REGN2477 in Healthy Women Not of Childbearing Potential</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the safety and tolerability of single
      ascending doses of REGN2477 in healthy women not of childbearing potential.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">January 12, 2017</completion_date>
  <primary_completion_date type="Actual">January 12, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment emergent adverse events (TEAEs) through day 113 in participants treated with REGN2477</measure>
    <time_frame>Day 1 to Day 113</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of REGN2477, assessed via serum concentrations of REGN2477 over time</measure>
    <time_frame>Day 1 to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of REGN2477, as determined by the presence or absence of Anti-drug antibody (ADA) to REGN2477 over time</measure>
    <time_frame>Day 1 to Day 113</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>REGN2477</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts 1 - 5 will receive REGN2477</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts 1 - 5 will receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN2477</intervention_name>
    <description>Participants will receive ascending doses of REGN2477</description>
    <arm_group_label>REGN2477</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy women not of childbearing potential between 18 and 65 years of age, with no
             significant health issues or clinically significant abnormal laboratory findings

          2. A body mass index (BMI) between 18 to 30 kg/m2, inclusive

          3. Provide a signed informed consent

        Exclusion Criteria:

          1. Significant illness or history of significant illness

          2. Clinically significant abnormal CBC, clinical chemistry, and urine analysis at
             screening

          3. Current smoker or former smoker who has stopped smoking within 3 months prior to
             screening

          4. Positive urine drug test results during screening, or history of drug or alcohol abuse

          5. Donation or loss of, blood within 8 weeks prior to screening, or plasma up to 14 days
             prior to screening

          6. History of diabetes

          7. Abnormal blood pressure (BP)

          8. History of gynecological disorders or malignancies; history of breast malignancies; or
             history of benign gynecological or breast lesions that require medical treatment or
             follow up

          9. Reduced renal function

         10. Known history of chronic hepatitis or HIV

         11. Clinically significant ECG abnormalities

         12. Participation in any clinical research study within 30 days, or 5 halflives, of the
             study drug, whichever is greater, or for longer periods per regional requirements,
             prior to the screening visit

         13. Exposure to any biological drugs within 3 months of the screening visit (the name of
             the drug and duration of previous exposure will be recorded). Vaccination within 4
             weeks of screening visit.

         14. History of hypersensitivity reactions to vaccines or other biologics

         15. History of hypersensitivity to doxycycline or other tetracycline antibiotics

         16. History of osteoporosis requiring osteoporosis treatments such as PTH,
             bisphosphonates, and denosumab

         17. Subject using hormone replacement therapy or thyroid replacement therapy will be
             excluded, unless they have been on stable doses of such therapy for at least 6 months
             and will remain on the same stable dose through the duration of the trial

         18. Use of systemic glucocorticoids, including oral glucocorticoids, for more than 10
             days, within 3 months prior to screening.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2016</study_first_submitted>
  <study_first_submitted_qc>August 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2016</study_first_posted>
  <last_update_submitted>February 16, 2017</last_update_submitted>
  <last_update_submitted_qc>February 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

